Abstracts Archive - Page 1911 of 2425 - ACR Meeting Abstracts

Abstract Number: 2117 • 2014 ACR/ARHP Annual Meeting
Association Between Depression and High Utilization of Emergency Department in Patients with Systemic Lupus Erythematosus from the Southeastern United States: The Goal Cohort
Alfredo Aguirre¹, S. Sam Lim², Gaobin Bao³, Charles T. Molta⁴, Hong Kan⁵ and Cristina Drenkard⁶, ¹Department of Rheumatology, Emory University, Atlanta, GA, ²Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, ³Medicine, Emory University, Atlanta, GA, ⁴GlaxoSmithKline, King of Prussia, PA, ⁵5 Moore Dr, GSK, Durham, NC, ⁶Medicine, Div Rheumatology, Emory University, Atlanta, GA
Background/Purpose . Frequent visitors of the emergency department (ED) among the general population share several demographic, health system and disease characteristics, including older age, poverty,…
Abstract Number: 2118 • 2014 ACR/ARHP Annual Meeting
Lower Socioeconomic Status at Disease Onset Is Associated with Higher Health Care Costs in Patients with Systemic Lupus Erythematosus: A General Population-Based Cohort Study
Natalie McCormick¹, Mohsen Sadatsafavi², Wenjia Chen³, Carlo A. Marra⁴ and J. Antonio Avina-Zubieta⁵, ¹Faculty of Pharmaceutical Sciences, University of British Columbia/Arthritis Research Centre of Canada, Vancouver, BC, Canada, ²Division of Respiratory Medicine, University of British Columbia, Vancouver, BC, Canada, ³Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁴Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: Low socioeconomic status (SES) negatively impacts health outcomes in the general population, as well as in systemic lupus erythematosus (SLE), but the impact on…
Abstract Number: 2119 • 2014 ACR/ARHP Annual Meeting
Off Work Days Decreased RATE in Muskuloeskeletal Disease Patients: Usefulness of the EARLY Intervention Program
Francisco Miguel Ortiz Sanjuan, Isabel Martinez-Cordellat, Jose Ivorra, Jose Luis Valero, Inmaculada Chalmeta, Elena Grau, Carlos Feced, Rosa Negueroles, Luis Gonzalez-Puig, Cristobal Nuñez-Cornejo Piquer, Cristina Alcañiz, Eztizen Labrador and Jose Andres Roman Ivorra, Department of Rheumatology, Hospital Universitario y Politécnico La Fe., Valencia, Spain
Background/Purpose In March 2012, a new project was started at HUP La Fe following the pilot project carried out at San Carlos Clinical Hospital in…
Abstract Number: 2120 • 2014 ACR/ARHP Annual Meeting
Societal Preferences for Rheumatoid Arthritis Treatments. Evidence from a Discrete Choice Experiment
Mark Harrison^1,2, Carlo Marra³, Kam Shojania⁴ and Nick Bansback⁵, ¹University of Manchester, Manchester, United Kingdom, ²University of British Columbia, Vancouver, BC, Canada, ³Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁴Medicine, University of British Columbia, Vancouver, BC, Canada, ⁵School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Background/Purpose The cost-effectiveness of new interventions is increasingly assessed using the cost per quality-adjusted life year (QALY). QALYs are calculated by multiplying the length of…
Abstract Number: 2121 • 2014 ACR/ARHP Annual Meeting
Real-World Cost Comparison of Urate Lowering Therapies in Patients with Gout and Moderate to Severe Chronic Kidney Disease
Ghaith Mitri¹, Eric Wittbrodt¹, Robin Turpin¹, Beni Tidwell² and Kathy Schulman², ¹Medical Affairs, Takeda Pharmaceuticals International, Deerfield, IL, ²Outcomes Research Solutions, Inc., Waltham, MA
Background/Purpose Gout flare prevention relies heavily on urate-lowering therapies (ULT) such as allopurinol (ALP) and febuxostat (FBX) but clinical decision-making in patients with moderate to…
Abstract Number: 2122 • 2014 ACR/ARHP Annual Meeting
Variation in the Prescribing Practices of Biologic Dmards
Heather O. Tory¹, Josephine A. Awosogba², Amish J. Dave², Jonathan S. Coblyn², Daniel H. Solomon² and Sonali P. Desai², ¹Rheumatology Program, Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Biologic DMARDs (bDMARDs) are effective yet expensive treatments for RA. Variability in the prescribing practices of rheumatologists using these agents may be attributable to…
Abstract Number: 2123 • 2014 ACR/ARHP Annual Meeting
Significant State-Level Variation in Source of Biologic Drug Coverage Among Beneficiaries with Rheumatoid Arthritis
Chris Tonner¹, Gabriela Schmajuk² and Jinoos Yazdany², ¹3333 California Street, Box 09, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA
Background/Purpose: Biologic drugs can be obtained both through Medicare's Part B medical benefit (physician administered drugs) or Part D pharmacy benefit (self-administered drugs). Coverage for…
Abstract Number: 2124 • 2014 ACR/ARHP Annual Meeting
Characteristics of Medicare Beneficiaries Travelling Long Distances to Visit a Rheumatologist
Gabriela Schmajuk¹, Chris Tonner² and Jinoos Yazdany³, ¹Medicine / Rheumatology, UCSF / San Francisco VA, San Francisco, CA, ²3333 California Street, Box 09, University of California, San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA
Background/Purpose: Studies of the distribution of rheumatologists across the United States suggest that a significant number of patients travel long distances to visit a rheumatologist. …
Abstract Number: 2125 • 2014 ACR/ARHP Annual Meeting
Burden of Illness in Refractory Gouty Arthritis: A One-Year Prospective Multinational, Observational Study
Louis Bessette¹, Frédéric Lioté², Carmen Moragues³, Rüdiger Moericke⁴, Zhang Zhiyi⁵, Alberto Ferreira⁶, Pascal Lecomte⁶, Sophia Kessabi⁶, Haijun Tian⁷ and Jasvinder A. Singh^8,9, ¹CHUL, Quebec, QC, Canada, ²Hôpital Lariboisière & University Paris Diderot, Paris, France, ³Hospital Platón, Barcelona, Italy, ⁴Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ⁵The First Affiliated Hospital of Haerbin Medical University, Haerbin, China, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Mayo Clinic, Rochester, MN, ⁹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Refractory gouty arthritis (RGA) is a condition characterized by appearance of recurrent flares and contraindication, intolerance, or lack of efficacy to first-line anti-inflammatory therapy…
Abstract Number: 2126 • 2014 ACR/ARHP Annual Meeting
The Utility of Digital Activity Fluorescence Optical Imaging in Quantifying Hand and Wrist Inflammation in Rheumatic Diseases
Yogan Kisten¹, Noémi Györi¹, Hamed Rezaei^2,3, Adrian Levitsky⁴, Anna Karlsson¹, Erik af Klint³ and Ronald van Vollenhoven^3,5, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute,Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Stockholm, Sweden, ²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The rheumatology clinic of the Karolinska University Hospital, Stockholm, Sweden, ⁴The Karolinska Institute,Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Stockholm, Sweden, ⁵Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden
Background/Purpose The objective detection and quantification of disease activity in its earliest pathophysiological stage is critical for achieving optimal therapy results. Fluorescence optical imaging (FOI)…
Abstract Number: 2127 • 2014 ACR/ARHP Annual Meeting
Subclinical Arthritis Is Detected By Macrophage Targeting and Positron Emission Tomography (PET) in Early RA Patients in Clinical Remission
Y.Y.J. Gent¹, M.M. ter Wee¹, D den Uyl¹, N. Ahmadi², W.F. Lems³, O.S. Hoekstra⁴, A.E. Voskuyl¹ and C.J. Van der Laken³, ¹Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ²Radiology, VU University Medical Center, Amsterdam, Netherlands, ³Rheumatology, VU Medical Center, Amsterdam, Netherlands, ⁴Nuclear Medicine, VU Medical Center, Amsterdam, Netherlands
Background/Purpose: Recurrent flares in RA patients in complete remission (CR) are not an uncommon phenomenon. Studies with advanced imaging techniques have suggested that residual subclinical…
Abstract Number: 2128 • 2014 ACR/ARHP Annual Meeting
Effectiveness of ¹⁸f-Fluoro-Dexoxyglucose Positron Emission Tomography for the Diagnosis of Polymyalgia-like Illness
Hideyuki Horikoshi¹, Takashi Nakanishi¹, Reiko Takahashi¹, Fumihiko Kimura² and Kenji Itoh¹, ¹Division of Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan, ²National Defense Medical College, Tokorozawa, Japan
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory condition that affects the elderly. It is characterized by pain and stiffness in the shoulder and pelvic girdles. …
Abstract Number: 2129 • 2014 ACR/ARHP Annual Meeting
Sensitivity and Specificity of the “Green Nail” Sign in Fluorescence Optical Imaging in Psoriatic Arthritis
Oliver Wiemann¹, Stephanie G. Werner¹, Hannah Röver¹, Gudrun Lind-Albrecht¹, Sabine Mettler¹, Marina Backhaus² and Hans-Eckhard Langer¹, ¹RHIO (Rheumatology, Immunology, Osteology), Duesseldorf, Germany, ²Rheumatology/Immunology, Charite University Hospital, Berlin, Germany
Background/Purpose ICG-enhanced fluorescence optical imaging (FOI) is a novel technology for the assessment of inflammation in arthritis [1,2]. Recent work suggested that a “green nail”…
Abstract Number: 2105 • 2014 ACR/ARHP Annual Meeting
Nonsurgical Treatment Patterns in Patients with Chronic Spinal Cord Injury
Brian Le¹, Monique Bethel², Lauren Bailey³, Frances Weaver³, Stephen Burns⁴, Jelena Svircev⁴, Michael Heggeness⁵ and Laura Carbone⁶, ¹Medicine, Georgia Regents University, Augusta, GA, ²Internal Medicine, Georgia Regents University, Augusta, GA, ³Edward Hines Jr. VA Hospital, Chicago, IL, ⁴VA Puget Sound Healthcare System, Seattle, WA, ⁵Orthopaedic Surgery, University of Kansas School of Medicine, Kansas City, KS, ⁶Medicine, Charlie Norwood VA Medical Center, Augusta, GA
Background/Purpose: Sublesional loss of bone mineral density is a common complication in patients with chronic spinal cord injury (SCI) putting them at high risk for…
Abstract Number: 2104 • 2014 ACR/ARHP Annual Meeting
Effectiveness of a Workplace Integrated Care Intervention on Work Productivity in Workers with Rheumatoid Arthritis
Myrthe van Vilsteren^1,2, Cécile Boot^1,2, Dirkjan van Schaardenburg³, Romy Steenbeek^2,4, A.E. Voskuyl⁵ and Johannes Anema^1,2,6, ¹Department of Public and Occupational Health, EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands, ²Body@Work, Research Center Physical Activity, Work and Health, TNO-VU University Medical Center, Amsterdam, Netherlands, ³Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ⁴TNO Work and Health, Hoofddorp, Netherlands, ⁵Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁶Research Center for Insurance Medicine AMC-UMCG-UWV-VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease with a profound impact on a person’s working life. Besides permanent work disability and sick leave,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].